- Home
- GNTA vs PSNL Comparison
GNTA vs PSNL Comparison
Compare GNTA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- PSNL
- Stock Information
- Founded
- GNTA 2014
- PSNL 2011
- Country
- GNTA Italy
- PSNL United States
- Employees
- GNTA N/A
- PSNL N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- PSNL Medical Specialities
- Sector
- GNTA Health Care
- PSNL Health Care
- Exchange
- GNTA Nasdaq
- PSNL Nasdaq
- Market Cap
- GNTA 67.4M
- PSNL 321.1M
- IPO Year
- GNTA 2021
- PSNL 2019
- Fundamental
- Price
- GNTA $5.34
- PSNL $5.19
- Analyst Decision
- GNTA Strong Buy
- PSNL Strong Buy
- Analyst Count
- GNTA 1
- PSNL 4
- Target Price
- GNTA $25.00
- PSNL $6.81
- AVG Volume (30 Days)
- GNTA 28.4K
- PSNL 439.4K
- Earning Date
- GNTA 01-01-0001
- PSNL 11-06-2024
- Dividend Yield
- GNTA N/A
- PSNL N/A
- EPS Growth
- GNTA N/A
- PSNL N/A
- EPS
- GNTA N/A
- PSNL N/A
- Revenue
- GNTA N/A
- PSNL $80,027,000.00
- Revenue This Year
- GNTA N/A
- PSNL $10.85
- Revenue Next Year
- GNTA N/A
- PSNL $8.77
- P/E Ratio
- GNTA N/A
- PSNL N/A
- Revenue Growth
- GNTA N/A
- PSNL 19.20
- 52 Week Low
- GNTA $2.20
- PSNL $0.89
- 52 Week High
- GNTA $7.28
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- GNTA 56.89
- PSNL 56.29
- Support Level
- GNTA $4.89
- PSNL $4.54
- Resistance Level
- GNTA $6.20
- PSNL $5.35
- Average True Range (ATR)
- GNTA 0.70
- PSNL 0.30
- MACD
- GNTA -0.06
- PSNL 0.05
- Stochastic Oscillator
- GNTA 37.32
- PSNL 84.71
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.